Candida Arthritis: Analysis of 112 Pediatric and Adult Cases

Maria N. Gamaleldou,1,2,6 Blandine Rammaert,4,6,8 Marimelle A. Bueno,1 Nikolaos V. Sipsas,2,3 Brad Moriyama,9 Dimitrios P. Kontoyiannis,7 Emmanuel Roilides,3,9 Valerie Zeller,7 Saad J. Taj-Aldeen,10 Andy O. Miller,1,3,11 Ruta Petraitiene,1 Olivier Lortholary,3,4 and Thomas J. Walsh1,3,11

1Weill Cornell Medicine of Cornell University, Departments of Medicine, Pediatrics, and Microbiology & Immunology, New York, New York; 2National and Kapodistrian University of Athens, Greece; 3Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, New York; 4Université Paris-Descartes, Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Service des Maladies Infectieuses et Tropicales, Hôpital Necker-Enfants Malades, Centre d’Infectiologie Necker-Pasteur, Institut Imagine, and 5Unité de Mycologie Moléculaire, Institut Pasteur, Paris, France; 6Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, Maryland; 7MD Anderson Cancer Center, Houston, Texas; 83rd Department of Pediatrics, Aristotle University School of Health Sciences and Hippokration General Hospital, Thessaloniki, Greece; 9Osteoarticular Reference Center, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France; 10Mycology Laboratory, University of Doha, Qatar; and 11Hospital for Special Surgery, New York, New York

Background. Candida arthritis is a debilitating form of deeply invasive candidiasis. However, its epidemiology, clinical manifestations, management, and outcome are not well understood.

Methods. Cases of Candida arthritis were reviewed from 1967 through 2014. Variables included Candida spp in joint and/or adjacent bone, underlying conditions, clinical manifestations, inflammatory biomarkers, diagnostic imaging, management, and outcome.

Results. Among 112 evaluable cases, 62% were males and 36% were pediatric. Median age was 40 years (range, <1–84 years). Most patients (65%) were not pharmacologically immunosuppressed. Polyarticular infection (≥3 joints) occurred in 31% of cases. Clinical manifestations included pain (82%), edema (71%), limited function (39%), and erythema (22%) with knees (75%) and hips (15%) most commonly infected. Median erythrocyte sedimentation rate was 62 mm/hr (10–141) and C reactive protein 26 mg/dL (0.5–98). Synovial fluid median white blood cell count was 27 500/µL (range, 100–500 000/µL) with 90% polymorphonuclear neutrophils (range, 24–98). Adjacent osteomyelitis was present in 30% of cases. Candida albicans constituted 63%, Candida tropicalis 14%, and Candida parapsilosis 11%. Most cases (66%) arose de novo, whereas 34% emerged during antifungal therapy. Osteolysis occurred in 42%, joint-effusion in 31%, and soft tissue extension in 21%. Amphotericin and fluconazole were the most commonly used agents. Surgical interventions included debridement in 25%, irrigation 10%, and drainage 12%. Complete or partial response was achieved in 96% and relapse in 16%

Conclusion. Candida arthritis mainly emerges as a de novo infection in usually non-immunosuppressed patients with hips and knees being most commonly infected. Localizing symptoms are frequent, and the most common etiologic agents are C albicans, C tropicalis, and C parapsilosis. Management of Candida arthritis remains challenging with a clear risk of relapse, despite antifungal therapy.

Keywords. antifungal therapy; arthritis; Candida spp; diagnosis; invasive candidiasis.

Among the causes of septic arthritis, fungal arthritis occurs infrequently and is most commonly caused by Candida species [1, 2]. Early reports suggested that Candida arthritis most commonly develops as a complication of disseminated candidiasis [3–6]. However, little is known about the clinical settings, laboratory features, radiological characteristics, or management of this uncommon infection.

Most reports of Candida arthritis are limited to individual case descriptions and relatively small case series. There is no comprehensive analysis that addresses the demographic, clinical, orthopedic, laboratory, microbiology, diagnostic imaging, and therapeutic aspects of this infection. Moreover, the possible mechanisms of infection that lead to Candida arthritis also are not well understood.

Therefore, we conducted a systematic review of 112 reported cases of Candida arthritis that fulfilled prespecified criteria. Our objective was to describe the demographics, mechanisms of infection, clinical manifestations, osteoarticular distribution, microbiology, inflammatory biomarkers, diagnostic imaging, management, and outcome of Candida arthritis.

PATIENTS AND METHODS

Search Strategy

We initiated our search by reviewing the English references as published in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) using the following key words: Candida, candidiasis, nonprosthetic arthritis, and osteomyelitis. We then carefully included only the well described references of single case reports or
case series. After this initial series of reports was reviewed, individual references listed in each publication were again reviewed for ascertainment of additional case reports.

**Study Population**

We reviewed only the well described reported cases of native nonprosthetic *Candida* arthritis as published in the English literature within the study period 1967–2014. Data regarding epidemiology, clinical and radiological features, demographic characteristics, management, and outcome of the patients were collected and presented with descriptive statistics to determine the risk factors of *Candida* arthritis.

**Criteria for Inclusion of Cases of *Candida* Arthritis**

Cases selected in the initial screen were then included in the final analysis if the following data were available: demographics, underlying condition, documentation of native *Candida* arthritis and anatomical location of infection, microbiology data, radiology findings, symptomatology, therapeutic intervention, and outcome.

**Definitions**

**Direct Inoculation**

Direct inoculation is defined as seeding of synovial fluid by trauma or surgical manipulation.

**Hematogenous**

Hematogenous is defined as seeding of synovial fluid by the bloodstream route. Patients with documented *Candida* arthritis with candidemia or disseminated candidiasis were classified as having a hematogenous mechanism of infection of the involved joint. In the absence of documented candidemia or proven disseminated candidiasis, patients who did not have a clear history of contiguous infection were classified as having hematogenous infection of the joint as the most plausible mechanism.

**Contiguous**

Contiguous is defined as seeding of synovial fluid from an adjacent *Candida* infection.

**Proven *Candida* Arthritis**

Proven *Candida* arthritis is defined as a patient with evidence of a positive culture and/or histology from synovial fluid analysis.

**Probable *Candida* Arthritis**

Probable *Candida* arthritis is defined as a patient with evidence of a positive culture, and/or histology from other than a synovial fluid specimen, such as bone, cartilage, bone marrow, adjacent abscess, blood, central venous catheter, thrombus, tendon, disc, or operative samples, associated with compatible clinical and radiological features.

**Breakthrough *Candida* Arthritis**

Breakthrough *Candida* arthritis is defined as a patient receiving systemic antifungal agents before or at the onset of *Candida* arthritis.

**De novo *Candida* Arthritis**

De novo *Candida* arthritis is defined as a patient not receiving systemic antifungal therapy when the episode of *Candida* arthritis occurred.

**Complete Response**

Complete response is defined as complete resolution of clinical and radiological findings of arthritis, as assessed by 2 authors (M.N.G., M.A.B.) and, where warranted, a third author (T.J.W.).

**Partial Response**

Partial response is defined as partial resolution of clinical and/or radiological findings of arthritis or partial clinical improvement without availability of radiological data, as assessed by 2 authors (M.N.G., M.A.B.) and, where warranted, a third author (T.J.W.).

**Data Collection and Analysis**

Data regarding demographic characteristics, clinical and radiological features, inflammatory biomarkers, microbiology, management, and outcome of patients were collected and analyzed with descriptive statistics using Instat GraphPad (GraphPad Software, San Diego, CA). Continuous variables were summarized using median and range, whereas categorical variables were summarized using frequencies and percentages. Differences in proportions were analyzed by Fisher’s exact test. A *P* value of ≤.05 was considered to be significant.

**RESULTS**

**Literature Review**

Patients included in this study consisted of 112 nonprosthetic *Candida* arthritis cases as published in the English literature within the study period from 1967 to 2014. The first case of *Candida* arthritis was reported in 1967 [71]. Since this initial report through 2014, a total of 112 published cases [7–103] of *Candida* arthritis fulfilled predefined criteria for evaluability. Thus, 112 evaluable cases were entered into the database.

**Demographic Characteristics and Underlying Conditions**

Amongst a total of 112 published cases of *Candida* arthritis, median age was 40 years (range, ≤1 month–84 years) (Table 1). Sixty-nine patients (62%) were males. Underlying conditions included surgery (35%), hematologic malignancies (16%), solid organ transplantation ([SOT] 9%), trauma (9%), intravenous drug use (9%), and solid tumors (4%). The majority of patients was not neutropenic nor was receiving corticosteroids or other pharmacological immunosuppression. Other conditions included central venous catheters, prior broad-spectrum antibiotics or antifungal agents, total parenteral nutrition, critical illness, use of illicit intravenous drugs or alcohol abuse, diabetes mellitus, hemodialysis, chronic pulmonary disease, and hypogammaglobulinaemia. Ten patients (9%) had trauma or open wounds.

**Candidemia and Arthritis**

Before the diagnosis of *Candida* arthritis, 71 (63%) patients initially had candidemia or other form of candidiasis, including
Table 1. Demographic Characteristics and Underlying Conditions of Nonprosthetic Candida Arthritis (N = 112)

| Demographic Features and Underlying Conditions                      | N (%) |
|---------------------------------------------------------------------|-------|
| Median age (neonates-84 years)                                      |       |
| Adults (≥19 years)                                                  | 72 (64)|
| Pediatric population                                               | 40 (36)|
| Neonates (≤1 months)                                                | 11 (10)|
| Infants (≤12 months)                                                | 17 (15)|
| Toddlers/Children (1–18 years)                                     | 10 (9) |
| Unknown age                                                         | 2 (2)  |
| Gender                                                              |       |
| Females                                                             | 37 (33)|
| Males                                                               | 69 (62)|
| Unknown                                                             | 6 (5)  |
| Underlying conditions                                               |       |
| Solid tumors                                                        | 5 (4)  |
| Hematologic malignancy                                              | 19 (16)|
| Aplastic anemia                                                     | 1 (1)  |
| Solid organ transplantation                                          | 10 (9) |
| Bone marrow transplantation                                          | 3 (3)  |
| Surgery                                                             | 39 (35)|
| Facial/Neck                                                         | 0 (0)  |
| Thoracic                                                            | 4 (4)  |
| Abdominal                                                           | 20 (18)|
| Orthopedic                                                          | 15 (13)|
| Prior broad-spectrum antibiotics                                    | 73 (65)|
| Prior antifungal agents                                             | 35 (31)|
| Central venous catheter                                             | 17 (15)|
| Open fracture                                                       | 0 (0)  |
| Trauma/open wound                                                   | 10 (9) |
| HIV                                                                 | 4 (4)  |
| IVDU                                                                | 10 (9) |
| Alcohol abuse                                                       | 5 (4)  |
| Hemodialysis                                                        | 6 (5)  |
| Neutropenia                                                         | 10 (9) |
| Corticosteroids                                                     | 20 (18)|
| Pharmacological immunosuppression other than steroids               | 19 (17)|
| Hypogammaglobulinemia                                               | 2 (2)  |
| Chronic Pulmonary Disease                                           | 4 (4)  |
| Abdominal abscess                                                   | 1 (1)  |
| GI rupture                                                          | 1 (1)  |
| Necrotic enterocolitis                                              | 2 (2)  |
| Congenital disorder (gastrochisis, Hirschsprung’s disease)          | 7 (6)  |
| Total parenteral nutrition                                          | 14 (13)|
| Diabetes mellitus                                                   | 11 (10)|
| Rheumatoid arthritis                                                | 2 (2)  |
| Intensive care unit                                                 | 6 (5)  |
| None                                                                | 3 (3)  |
| Preexisting invasive candidiasis                                    | 71 (63)|
| Candidemia                                                          | 32 (29)|
| Other forms of candidiasia                                          | 39 (35)|
| Candidemia at time of diagnosis of Candida arthriti                 | 12 (11)|

Abbreviations: CNS, central nervous system; GI, gastrointestinal; HIV, human immunodeficiency virus; IVDU, intravenous drug use.

* Central venous catheter infection, candiduria, orbital candidiasis, and cutaneous, pulmonary, or CNS infection.

Table 2. Classification and Apparent Mechanisms of Nonprosthetic Candida Arthritis

| Classification and Apparent Mechanisms                          | N (%) |
|------------------------------------------------------------------|-------|
| Classification of Candida arthriti                               |       |
| Proven*                                                          | 99 (88)|
| Probable*                                                        | 13 (12)|
| Apparent mechanisms of infection                                 |       |
| Hematogenous                                                     | 91 (81)|
| Direct inoculation                                               | 21 (19)|
| Contiguous                                                       | 0 (0)  |
| Relation to antifungal therapy                                   |       |
| Breakthrough Candida arthriti                                    | 38 (34)|
| De novo Candida arthriti                                         | 74 (66)|

* Proven = specimen from synovial fluid analysis that isolated Candida.

* Probable = specimen that isolated Candida other than synovial fluid, plus (+) local symptoms (+) radiology. This specimen is bone tissue (3), or bone and cartilage (1), bone marrow (1), adjacent abscess (1), cartilage (1), thrombus (1), tendon (1), disc (1), or operative samples (1).

Central venous catheter infection, candiduria, orbital candidiasis, and central nervous system infection (Table 1). Twelve patients (11%) also had candidemia at the time of diagnosis of Candida arthriti.

Classification of Candida Arthritis and Mechanisms of Articular Infection

Ninety-nine cases (88%) were proven and 13 cases (12%) were probable for Candida arthriti (Table 2). Apparent mechanisms of Candida arthriti consisted of hematogenous dissemination (81%) and direct inoculation (19%). Breakthrough Candida arthriti accounted for 34% versus de novo infection in 66%; these 2 groups were mutually exclusive.

Osteoarticular Distribution

Monoarticular involvement occurred in 77 cases (69%), whereas 2 or more joints were infected in 35 cases (31%). Candida synovial arthriti involved the knee in 84 (75%) cases, hip in 17 (15%) cases, and shoulder in 8 (7%) patients (Table 3). The most frequently infected bone sites were femur (19%), tibia (13%), and humerus (8%).

Diagnostic Procedures

The following diagnostic approaches were used for patients with Candida arthriti: needle aspiration in 80 (71%); open biopsy or surgery in 12 (11%); and percutaneous, closed, or guided biopsy in 4 (4%) (Table 4). Candida species were detected predominantly via direct culture in 98 (88%) patients and less frequently by histopathology with or without culture (Table 4). One Candida species was recovered in 111 patients (99%) with arthriti, whereas in 1 (1%) patient more than 1 species of Candida was identified.

Clinical Microbiology

Candida albicans was identified in 63% of 112 cases of arthriti (Table 4). Among non-albicans species, Candida tropicalis was recovered in 14%, Candida parapsilosis in 11%, Candida krusei in 4%, followed by Candida glabrata in 2%, Candida lusitaniae...
in 2%, *Candida guilliermondii* in 2%, and nonspecified *Candida* species in 4%.

**Clinical Manifestations**

Ninety-two (82%) of 112 patients complained of local pain and tenderness, whereas 79 (71%) had edema, and 25 (22%) patients presented with localized erythema (Table 5). Fever was present in 15 (13%) patients. Limitation of function and movement was documented in 44 (39%) patients. Sinus tracts and draining pus were observed in 6 (5%) patients.

**Markers of Inflammation**

The median white blood cell (WBC) counts were mildly elevated with a median of 10,750 cells/mm$^3$ (range, 160–36,500 cells/mm$^3$) with neutrophils consisting of a median of 45% (10%–90%). By comparison, median values of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were moderately elevated at 56 mm/hour (range, 10–118 mm/hour) and highly elevated at 28.9 mg/dL (range, 0.5–141 mg/dL), respectively, with a wide range of variation (Table 5). For the synovial fluid, there was leukocytosis with predominance of neutrophils.

**Diagnostic Imaging**

The most common radiological abnormalities in *Candida* arthritis were bone destruction (42%) and joint effusion (31%), followed by extension into soft tissues, decrease of articular space, osteoarthritis and periosteal reaction, and/or synovitis (Table 6). Extension into soft tissue was also observed in 21%.

**Treatment and Outcome**

Sixty-nine (62%) patients with *Candida* arthritis were treated with antifungal agents only, 1 (1%) underwent surgical treatment only, and 40 (36%) were treated with both antifungal therapy and surgery. The most commonly used combinations of antifungal agents were amphotericin B plus anazole or amphotericin B plus flucytosine (Table 7). There was no significant difference between patients who received surgical intervention plus medical therapy versus those who received medical therapy alone ($p = .40$). However, there were fewer deaths in those treated with antifungal therapy plus surgery (2 [4%]) versus those treated with antifungal therapy alone (12 [14%]), 3 of which were caused by disseminated candidiasis.

Median duration of therapy was 64 days (range, 14–436 days). Debridement was the most common surgical procedure (25%) followed by drainage/aspiration and irrigation/lavage.
Complete response of *Candida* arthritis was documented in 87 patients (78%), partial response in 21 cases (19%), relapse in 18 (16%), and failure in 4 (4%) (Table 7).

### Analysis of Pediatric and Adult Patients

The majority (70%) of all pediatric patients with *Candida* arthritis were neonates and infants. There was a significant difference in the pathogenetic mechanisms of infection, because 38 (95%) of 40 pediatric patients versus 53 (74%) of 72 adult patients (*P* = .005) followed a hematogenous dissemination (Table 8). Children achieved a higher complete response rate to antifungal therapy than adults (*P* = .09). There were no other significant differences in features of *Candida* arthritis between pediatric and adult populations.

In attempting to further understand potential differences in pediatric and adult patients with *Candida* arthritis, the frequencies of underlying diseases were analyzed and found to be similar (*P* = .23). There was a total of 18 of 40 pediatric patients who had immunocompromising conditions, including neonates, hematological malignancies, and hematopoietic stem cell transplantation (HSCT) in comparison to 24 of 72 adults with hematological malignancies, HSCT, and SOT (Table 8).

### DISCUSSION

This study of 112 cases of nonprosthetic *Candida* arthritis demonstrated a wide range of underlying conditions and ages from neonates to >80 years old. Whereas 34% were immunocompromised, the majority of patients had no apparent underlying immune impairment. Although the majority of patients had candidemia or other causes of invasive candidiasis before or during the appearance of arthritis, 29 (26%) patients had no preexisting invasive candidiasis or concomitant candidemia at the time of diagnosis of *Candida* arthritis. Most episodes (81%) of *Candida* arthritis arose from hematogenous dissemination. *Candida albicans*, *C tropicalis*, and *C parapsilosis* were the most common causes of *Candida* arthritis. Local pain, tenderness, and edema were commonly observed; however, fever was uncommon (13%). Likewise, WBC count, ESR, and CRP were only moderately elevated in most patients. The most common radiological abnormalities in *Candida* arthritis were bone destruction and joint effusion. A complete response to medical therapy with or without surgery was achieved in 78%; however, the remainder had only partial response, failure, or relapsed, suggesting the need for better therapeutic approaches for this infection.

An early diagnosis of *Candida* arthritis is important to prevent joint destruction, preserve function, and determine length of therapy. Understanding the host factors, clinical manifestations, inflammatory markers, diagnostic imaging, and microbiology are essential to achieving those objectives.
Duration of Medical Treatment

Among the 43 cases of combination antifungal therapy, the following classes were used: azole-echinocandin (2), polyene-azole-echinocandin (3), and polyene-echinocandin (1). polyene-azole (20), polyene-flucytosine (13), polyene-azole-flucytosine (3), azole-flucytosine (8), and flucytosine (7). Combination therapy included the aforementioned antifungal classes in any combination.

Table 7. Treatment and Outcome of Nonprosthetic Candida Arthritis

| Treatment and Outcome | N (%) |
|-----------------------|-------|
| Medical Treatmenta    |       |
| Only antifungal agents | 69 (62) |
| Only surgery          | 1 (1)  |
| Antifungal agents and surgery | 40 (38) |
| Class of Antifungal Agent(s) Used |       |
| Amphotericin B         | 37 (33) |
| Triazoles              | 21 (19) |
| Flucytosine            | 8 (7)  |
| Combinationsb          | 43 (38) |
| Duration of Medical Treatmentc |       |
| Median duration in days (range, 14–436) | 64 days |
| Surgical Intervention  |       |
| Debridement            | 28 (25) |
| Drainage/aspiration    | 13 (12) |
| Irrigation/lavage      | 11 (10) |
| Amputation             | 3 (3)  |
| Bone grafting          | 1 (1)  |
| Insertion of metal hardware/prosthesis/arthroplasty | 1 (1) |
| Outcome                |       |
| Complete response      | 87 (78) |
| Partial response       | 21 (19) |
| Failure                | 4 (4)  |
| Relapse                | 18 (16) |
| Overall mortality      | 15 (13) |

a Two cases received no therapy.
b Among the 43 cases of combination antifungal therapy, the following classes were used: polyene-azole (20), polyene-flucytosine (13), polyene-azole-flucytosine (3), azole-flucytosine (1), azole-echinocandin (2), polyene-azole-echinocandin (3), and polyene-echinocandin (1).
c Forty-six cases of unknown duration.

The age range, gender distribution, and underlying host factors of Candida arthritis reflect those of candidemia and deeply invasive candidiasis. Candida arthritis needs to be included within the differential diagnosis of osteoarticular symptoms in patients with underlying immunosuppression, including those with hematological malignancies, SOT, HSCT, and corticosteroid therapy. Likewise, surgery and trauma, particularly in patients receiving broad-spectrum antibiotics and with implanted central venous catheters, constitute other clinical settings in which Candida arthritis may emerge.

Candida arthritis may appear as a late manifestation of disseminated candidiasis. Kim et al. [12] reported development of Candida arthritis 2 weeks after a chemotherapy-induced granulocytopenic period in the absence of any invasive manipulation. Joint swelling or arthralgia after recovery from neutropenia in febrile patients should raise clinical suspicion of fungal arthritis [4, 81].

The apparent pathogenesis of most cases of Candida arthritis is that of hematogenous dissemination to the joint. The mammalian synovium is extremely vascular and contains no limiting basement membrane, promoting easy access of blood contents to the synovial space. Therefore, hematogenous seeding of Candida may affect normal joints [104].

Although the exact pathogenesis of Candida arthritis remains to be further elucidated, the portal of entry may originate via contamination of central vascular catheters or from altered gastrointestinal microbial flora in the host with subsequent mucosal translocation and hematogenous dissemination [4, 24, 43]. Although infection of a joint is also possible via direct inoculation (surgery or intra-articular infection), hematogenous dissemination appears to be the most common mechanism of infection.

Hematogenous dissemination was significantly more common as a mechanism of Candida arthritis in children than in adults. This difference may be understood from the observation that all pediatric patients with Candida arthritis were neonates, infants, and toddlers. These populations are particularly vulnerable to the osteoarticular complications of candidemia, including Candida arthritis. The lack of closure of the epiphyseal plate in neonates, infants, and toddlers allows hematogenously disseminated organisms to extend into the joint space either directly through the articular cartilage or through the bony cortex of the joint capsule and then into the synovial space. Adults are more likely to have underlying surgical- and trauma-related portals of direct infection, hence accounting for these differences in pediatrics.

Because this study found that Candida arthritis arises in most patients with known invasive candidiasis or at the time of diagnosis of candidemia, an evaluation of musculoskeletal symptoms in overall assessment may reveal localization to 1 or more joints. However, because Candida arthritis also may arise de novo in more than one fourth of patients, one needs to have a high index of reaching this diagnosis in patients with the aforementioned host factors as the first manifestation of disseminated disease.

The clinical manifestations of Candida arthritis of pain, tenderness, and edema are common and should prompt an assessment for septic arthritis with Candida joint infection high in the differential diagnosis in the setting of a susceptible host with or without other evidence of invasive candidiasis. The knee, hip, and shoulder are the most frequently infected sites. Moderately elevated ESR and CRP further support the diagnosis in most but not all patients. The radiological features of bone destruction and joint effusion attest to the virulent nature of Candida arthritis but are not specific.

Because the clinical manifestations and inflammatory markers are not specific for Candida arthritis, arthrocentesis or arthroscopy is warranted for the definitive diagnosis. Given the paucity of fever and specific laboratory findings or radiographic features, diagnosis of fungal osteoarticular infections may be delayed in most cases [109–111]. The differential diagnosis includes bacterial septic arthritis and crystalline arthritis. Although arthrocentesis is readily performed in the knee, the procedure is more challenging in the hip and shoulder. Synovial fluid analysis in Candida arthritis is characterized by acute
inflammatory response with a predominance of neutrophils; however, this is not specific. By comparison, recovery of *Candida* spp provides a definitive diagnosis. It is noteworthy that *Candida* spp are seldom laboratory contaminants from normally sterile synovial fluid.

That *C. albicans* and *C. tropicalis* constituted the 2 most common organisms causing septic arthritis is consistent with their being the most virulent causes of hematogenous disseminated candidiasis [24,104]. The paucity of cases of *C. glabrata* arthritis, despite its constituting as much as one fourth of cases of candidemia, suggests that this organism may not have the necessary virulence factors needed to establish infection within synovial tissue. Possible virulence factors, such as adhesion molecules, cell wall hydrophobicity, as well as extracellular proteases and phospholipases differ in their properties and expression among *Candida* spp [111].

The objectives of treatment of *Candida* arthritis are to relieve symptoms, eradicate infection, prevent joint injury, and restore function. Unfortunately, there is no evidence-based standard treatment regimen for patients with fungal osteoarticular infections of native joints due to the heterogeneous spectrum of diseases and the relatively low frequency of this disease. Current guidelines recommend initial antifungal therapy with amphotericin B or fluconazole combined with surgical debridement [105]. Ambulatory antifungal therapy may be achieved with orally administered fluconazole. Medical therapy of *Candida* arthritis in this study most commonly began with amphotericin with or without combinations, such as flucytosine or fluconazole. Echinocandins were used as part of combination therapy in 6 patients but not used as monotherapy. However, given the activity of echinocandins on *Candida* biofilms [106–108], primary therapy with an echinocandin is a rational approach for initial medical management of *Candida* arthritis.

Surgery may also be an important adjunct to medical management of *Candida* arthritis. Treatment of *Candida* arthritis in this series was successful in the majority of patients with medical therapy alone; however, surgical intervention was considered to be warranted in 36% of patients. Because synovial fluid analysis and radiological features of *Candida* arthritis reveal this infection to be a supplicative destructive process, the surgical procedures used included irrigation, drainage, and debridement.

Although there was no significant difference in therapeutic response between those who received combined medical plus surgical therapy versus medical therapy alone, there were more deaths and disseminated candidiasis in the latter. These differences may be due to a lack of source control or more immunocompromised host. That the overall responses were similar between the 2 groups does not necessarily justify medical therapy alone for all patients. We hypothesize that there are some patients who will benefit from antifungal therapy plus adjunctive surgical intervention, whereas others may respond to medical therapy alone. The data warrant that each patient with *Candida* arthritis be assessed individually for combination medical-surgical therapy versus medical therapy alone. We suggest that a prospective study may help to further define the

---

**Table 8. Effect of Age on Effect by Site of Infection, Clinical Manifestations, and Outcome in *Candida* Arthritis**

| Population (N) | Mechanism (N) | Joint Sites (N) | Number of Sites Infected/Patient (N) | Clinical Manifestations (N) | Therapeutic Intervention (N) | Outcome (N) |
|----------------|---------------|-----------------|-------------------------------------|-----------------------------|-----------------------------|-------------|
| All pediatric patients (40) | Hematogenous (38)* | Knee (31) | 1 bone involved (20) | Local symptoms pain (22) | Only AFT (28) | CR (35) |
| Neonates (11) | Contiguous (0) | Hip (10) | 2 bones involved (8) | Edema (31) | Only Surgery (0) | PR (9)* |
| Hemato (5) | Direct inoculation (2) | Ankle (6) | ≥3 bones involved (15) | Erythema (6) | AFT + Surgery (11) | D (3) |
| HSCT (2) | | Elbow (4) | | Limitation of movement (20) | Debridement (4) | CR (2) |
| Adults (72) | Hematogenous (53)* | Shoulder (3) | | Fever (7) | Amputation (1) | D (3) |
| | Contiguous (0) | Others (4) | | Draining pus (2) | Drainage (5) | CR (2) |
| | Direct inoculation (19) | Wrist (1) | | | Lavage (4) | PR (3) |
| | | Carpus (1) | | | | CR (2) |
| | | Costochondral (1) | | | | |
| | | Intervertebral (1) | | | | |

* Abbreviations: AFT, antifungal therapy; CR, complete response; Hematol, hematological malignancies; HSCT, hematopoietic stem cell transplantation; PR, partial response; Rel, relapsed; D, death; SOT, solid organ transplantation; 5-FC, 5-fluorocytosine.
* Of the 5 patients with PR, 2 patients ultimately died.
* P = .005.
factors guiding the decision for surgical intervention in Candida arthritis.

The rationale for medical therapy alone versus combined medical and surgical intervention in individual cases was not apparent in most reports. Although combined medical and surgical intervention is certainly considered a standard of care for septic arthritis, serious comorbidities could preclude surgery in some patients. That the overall therapeutic response was favorable in those treated with medical therapy alone, these data raise the question of whether there is a subset of patients who may be candidates for medical therapy on an individualized basis.

Lack of a favorable response to treatment with antibiotics in a possible septic arthritis, particularly in immunocompromised patients, should raise suspicion of a Candida osteoarticular infection. Prompt therapy in immunocompromised hosts presenting with acute arthritis should include not only antibacterial but also antifungal agents after diagnostic arthrocentesis.

An important pattern of therapeutic response was observed in those patients classified as “relapsed.” Upon discontinuation of a course of antifungal therapy, relapsed infection developed in 18 patients. However, all of such patients subsequently responded to a second course of antifungal therapy with or without further surgical intervention, suggesting that duration of therapy as well as adequate debridement and drainage are important for successful outcome. The optimal duration of antifungal therapy remains to be defined with individual considerations of immune impairments, type of joint, and adequacy of debridement. The report by Miller et al [112] also suggests that local intraoperative irrigation of an infected joint by amphotericin B may assure further local control.

Duration of therapy in this study extended a median period of 2 months. This duration is compatible with the previously reported length of therapy of approximately 3 months reported for Candida osteomyelitis [109]. That this duration may be decreased by aggressive joint irrigation or arthroscopic debridement is suggested by a recent study by Miller et al [112], who reported a median duration of approximately 2 months for treatment of Candida osteoarticular infections. Alternatively, induction therapy with an echinocandin and maintenance therapy with more potent triazoles, such as voriconazole, posaconazole, and isavuconazole, warrants further investigation for also reducing the duration of antifungal therapy.

This study design of Candida arthritis has several limitations. Due to the retrospective nature of the design, not all data points were uniformly obtained and documented. Although the study design is strengthened by the detail afforded in individual case reports, it also may be affected by publication bias, which may lead to the reporting of better outcomes. The lack of a denominator in the study design precludes establishing an estimate of incidence; however, this was not the objective of this study. Although the comprehensive nature of the study design from the earliest reported case to the present time increases an understanding of the clinical manifestations, it introduces variations in advances of imaging and treatment. Although a prospective, multicenter, case-controlled observational study would address many of these concerns, such a design for Candida arthritis would require years of data collection. Therefore, the study design used in this review provides for a large number of protocol-selected patients analyzed through a finely detailed database to advance our understanding of this uncommon osteoarticular infection.

**CONCLUSIONS**

In summary, this systematic review provides a comprehensive analysis of the demographic characteristics, host factors, clinical manifestations, inflammatory biomarkers, diagnostic imaging, microbiology, and treatment of 112 cases of Candida arthritis. A high index of clinical and microbiological suspicion of Candida spp in the differential diagnosis of septic arthritis in vulnerable hosts may facilitate the timely diagnosis and rapid initiation of the appropriate therapy.

**Acknowledgments**

T. J. W. is a Scholar of the Save Our Sick Children Foundation and a Scholar of the Sharp Family Foundation in Pediatric Emerging Infectious Diseases.

**Financial support.** This work was funded by Scholar of the Save Our Sick Children Foundation (to T. J. W.), Sharp Family Foundation (to T. J. W.), Special Account for Research Funds (to M. N. G. and N. V. S.) of the National and Kapodistrian University of Athens, and National Institutes of Health through an MD Anderson Cancer Center Support Grant (CA016672) (to D. P. K.).

**Potential conflicts of interest.** D. P. K. is a consultant and board member and received payment for lectures from Schering-Plough, Pfizer, and Astellas Pharma US. D. P. K. has also received grant support from Astellas Pharma US and Merck and has received an honorarium from Enzon Pharmaceuticals. T. J. W. has received research grants for experimental and clinical antimicrobial pharmacotherapeutics from Astellas, Cubist, Novartis, Pfizer, and Theravance. He also has served as consultant to Astellas, ContraFect, Cubist, Drais, iCo, Novartis, Pfizer, Methylgene, SigmaTau, and Trius. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Hansen BL, Andersen K. Fungal arthritis. A review. Scand J Rheumatol 1995; 24:248–50.
2. Bariteau JT, Waryasz GR, McDonnell M, et al. Fungal osteomyelitis and septic arthritis. J Am Acad Orthop Surg 2014; 22:390–401.
3. Murray HW, Faik MA, Roberts RB. Candida arthritis. A manifestation of disseminated candidiasis. Am J Med 1976; 60:857–95.
4. Fainstein V, Gilmore C, Hopfer RL, et al. Septic arthritis due to Candida species on patients with cancer: report of five cases and review of the literature. Rev Infect Dis 1982; 4:78–85.
5. Chen JY. Neonatal candidiasis associated with meningitis and endophthalmitis. Acta Paediatr Jpn 1994; 36:261–5.
6. Muñoz-Fernández S, Maciá MA, Pantoja L, et al. Osteoarticular infection in intravenous drug abusers: influence of HIV infection and differences with non drug abusers. Ann Rheum Dis 1993; 52:570–4.
7. Newsom SW, Lee WR, Rees JR. Fatal fungal infection following open-heart surgery. Br Heart J 1967; 29:457–60.
8. Larru B, Barrett DM, Gerber JS. Candida krusei arthritis in an adolescent with acute myelogenous leukemia. Pediatr Infect Dis J 2013; 32:1142–4.
9. Le Calloch R, Iannotto JC, Guillermo G, Tonneller JM. Fungal arthritis of the hip in patient with aplastic anemia. BMJ Case Rep 2013; 2013: pii: bcr2013008902.
31. Harris MC, Pereira GR, Myers MD, et al. Candidal arthritis in infants previously infected with Candida albicans in an infant with cystic fibrosis. J Med Microbiol 2011; 60:1542–5.

32. Weigl JA.

33. Zmierczak H, Goemaere S, Mielants H, et al. Candida tropicallis arthritis in a young patient without predisposing factors. J Bone Joint Surg Br 2000; 82:734–8.

34. Vicari P, Feitosa Pinheiro R, et al. Septic arthritis as the first sign of Candida septic arthritis. Clin Rheumatol 2003; 22:441–4.

35. Calvo Romero JM, Alvarez Vega JL, Salazar Vallinas JM, Ortega Alberdi R. Candida arthritis in an immunocompetent patient without predisposing factors. Clin Rheumatol 1998; 17:393–4.

36. Azaceta G, Olave T, de los Martires LD, et al. Successful lipid-complexed amphotericin B treatment of Candida arthritis in a lymphoma patient. Rev Esp Hematol 1996; 66:434–5.

37. Brooks DH, Puppazo F. Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. J Arthroplasty 1998; 13:707–12.

38. Pérez-Gómez A, Prieto A, Torresano M, et al. Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 1998; 27:226–44.

39. Hacimustafaoğlu M, Ener B, Tarım O, et al. Systemic candidiasis with acute Epstein-Barr virus infection. Acta Paediatr 1997; 86:1267–70.

40. Hacimustafaoğlu M, Ener B, Tarım O, et al. Systemic candidiasis with acute Epstein-Barr virus infection. Acta Paediatr 1997; 86:1267–70.

41. Swanson H, Hughes PA, Messer SA, et al. Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. J Pediatr 1996; 129:688–94.

42. Evdoridou J, Roulides E, Bibashi E, Kremenopoulos G. Multifocal osteoarthritis due to Candida parapsilosis in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997; 25:112–6.

43. Weers-Pothoff G, Havermans JF, Kamphuis J, et al. Candida tropicalis arthritis in a patient with acute myeloid leukaemia successfully treated with fluconazole: case report and review of the literature. Infection 1997; 25:109–11.

44. Azaceta G, Olave T, de los Martires LD, et al. Successful lipid-complexed amphotericin B treatment of Candida parapsilosis arthritis in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997; 25:112–6.

45. Calvo Romero JM, Alvarez Vega JL, Salazar Vallinas JM, Ortega Alberdi R. Candida arthritis in an immunocompetent patient without predisposing factors. Clin Rheumatol 1998; 17:393–4.

46. Brooks DH, Puppazo F. Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. J Arthroplasty 1998; 13:707–12.

47. Pérez-Gómez A, Prieto A, Torresano M, et al. Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 1998; 27:226–44.

48. Hacimustafaoğlu M, Ener B, Tarım O, et al. Systemic candidiasis with acute Epstein-Barr virus infection. Acta Paediatr 1997; 86:1267–70.

49. Weers-Pothoff G, Havermans JF, Kamphuis J, et al. Candida tropicalis arthritis in a patient with acute myeloid leukaemia successfully treated with fluconazole: case report and review of the literature. Infection 1997; 25:109–11.

50. Swanson H, Hughes PA, Messer SA, et al. Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. J Pediatr 1996; 129:688–94.

51. Nouyrigat P, Baume D, Blaise D, et al. Candida krusei arthritis in an in- flammatory arthritis of a total knee replacement. Acta Paediatr 2000; 89:529–31.

52. Calvo Romero JM, Alvarez Vega JL, Salazar Vallinas JM, Ortega Alberdi R. Candida arthritis in an immunocompetent patient without predisposing factors. Clin Rheumatol 1998; 17:393–4.

53. Brooks DH, Puppazo F. Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. J Arthroplasty 1998; 13:707–12.

54. Pérez-Gómez A, Prieto A, Torresano M, et al. Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 1998; 27:226–44.

55. Hacimustafaoğlu M, Ener B, Tarım O, et al. Systemic candidiasis with acute Epstein-Barr virus infection. Acta Paediatr 1997; 86:1267–70.
68. Katzenstein D. Isolated Candida arthritis: report of a case and definition of a distinct clinical syndrome. Arthritis Rheum 1985; 28:1421–4.

69. Mandel DR, Segal AM, Wysebeek AJ, Calabrese LH. Two unusual strains of Candida arthritis. Am J Med Sci 1984; 288:25–7.

70. Duquesnoy B, Fournier E, Berniere L, Delcambre B. Ketoconazole treatment for a case of Candida arthritis. J Rheumatol 1984; 11:105–11.

71. Ward RM, Sattler FR, Daloson AS Jr. Assessment of antifungal therapy in an 800-gram infant with Candida arthritis and osteomyelitis. Pediatrics 1983; 72:234–8.

72. Pope TL Jr. Pediatric Candida albicans arthritis: case report of hip involvement with a review of the literature. Prog Pediatr Surg 1982; 15:271–83.

73. Arnold HJ, Dini A, Jonas G, Zorn EL. Candida albicans arthritis in a healthy adult. South Med J 1981; 74:84–5.

74. Yousefzadeh DK, Jackson JH. Neonatal and infantile Candida arthritis with or without osteomyelitis: a clinical and radiographic review of 21 cases. Skeletal Radiol 1980; 5:77–90.

75. Gerster JC, Glause MP, Delacretaz F, Nguyen T. Erosive Candida arthritis in a patient with disseminated candidiasis. J Rheumatol 1980; 7:911–4.

76. Miro JM, Brancos MA, Abello R, et al. Costochondral involvement in systemic candidiasis in heroin addicts: clinical, scintigraphic, and histologic features in 26 patients. Arthritis Rheum 1988; 31:793–7.

77. Rao HK, Myers GJ. Candida meningitis in the newborn. South Med J 1979; 72:1468–71.

78. Svirsky-Fein S, Langer L, Milbauer B, et al. Neonatal osteomyelitis caused by Candida tropicalis in a two month old infant receiving parenteral nutrition. Int J Infect Dis 2004; 8:307–10.

79. Adkins SF, Fried J, Mahowald ML. Neonatal arthritis treated with 5-flucytosine. N Y State J Med 1979; 79:131–7.

80. Yarchoan R, Davies SF, Fried J, Mahowald ML. Isolated Candida arthritis. Arthritis Rheum 1977; 20:257.

81. Gamaletsou MN, Rammaert B, Bueno MA, et al. Epidemiology, clinical manifestations and use of amphotericin B. J Bone Joint Surg Am 1975; 57:157–60.

82. Farrell JB, Person DA, Lidsky MD, et al. Report of two cases and review of the literature. J Bone Joint Surg Am 1975; 57:157–60.

83. Marmor L, Peter JH. Candida arthritis of the knee joint. Clin Orthop Relat Res 1976; 111:133–5.

84. Fitzgerald E, Lloyd-Still J, Gordon SL. Candida arthritis. A case report and review of the literature. Clin Orthop Relat Res 1975; 106:143–7.

85. Poplack DG, Jacobs SA. Candida arthritis treated with amphotericin B. J Pediatr 1975; 87:989–90.

86. Freeman JB, Wienke JW, Soper RT. Candida osteomyelitis associated with intra-venous alimentation. J Pediatr Surg 1974; 9:783–4.

87. Hill HR, Mitchell TG, Matsen JM, Quie PG. Recovery from disseminated candidiasis in a premature neonate. Pediatrics 1974; 53:748–52.

88. Noble HB, Lyne ED. Candida osteomyelitis and arthritis from hyperalimentation therapy. Case report. J Bone Joint Surg Am 1974; 56:825–9.

89. Umber J, Chapman MW, Drutz DJ. Candida pyarthrosis. Report of a case and results of treatment with 5-flucytosine. J Bone Joint Surg Am 1974; 56:1520–4.

90. Lindström FD, Lindholm T. Candida albicans arthritis treated with flucytosine. Ann Intern Med 1973; 79:131.

91. Noyes FR, McCabe JD, Fekety FR Jr. Acute Candida arthritis. Report of a case and use of amphotericin B. J Bone Joint Surg Am 1973; 55:169–76.

92. Klein JD, Yamauchi T, Horlick SF. Neonatal candidiasis, meningitis, and arthritis: observations and a review of the literature. J Pediatr 1972; 81:31–4.

93. Lachman RS, Yamauchi T, Klein J. Neonatal systemic candidiasis and arthritis. Radiology 1972; 105:631–2.

94. Adler S, Randall J, Plotkin SA. Candida osteomyelitis and arthritis in a neonate. Am J Dis Child 1972; 125:595–6.

95. Pruitt AW, Achord JL, Fales FW, Patterson JH. Glucose-galactose malabsorption and joint involvement in a patient with disseminated candidiasis. J Rheumatol 1980; 7:911–4.

96. Noble HB, Lyne ED. Candida osteomyelitis and arthritis in a neonate. Am J Dis Child 1972; 125:595–6.

97. Frisch AW, Achord JL, Fales FW, Patterson JH. Glucose-galactose malabsorption complicated by monilial arthritis. Pediatrics 1969; 43:106–10.

98. Lindström FD, Lindholm T. Candida parapsilosis arthritis - assessment and use of amphotericin B. J Bone Joint Surg Am 1972; 55:169–76.

99. Noyes FR, McCabe JD, Fekety FR Jr. Acute Candida arthritis. Report of a case and use of amphotericin B. J Bone Joint Surg Am 1973; 55:169–76.

100. Yamauchi T, Horlick SF. Neonatal candidiasis, meningitis, and arthritis: observations and a review of the literature. J Pediatr 1972; 81:31–4.

101. Lachman RS, Yamauchi T, Klein J. Neonatal systemic candidiasis and arthritis. Radiology 1972; 105:631–2.

102. Adler S, Randall J, Plotkin SA. Candida osteomyelitis and arthritis in a neonate. Am J Dis Child 1972; 125:595–6.

103. Pope TL Jr. Pediatric Candida albicans arthritis - assessment of amphotericin B therapy. J Rheumatol 1978; 5:267–71.

104. Imbeau SA, Hanson J, Langgians G, D’Alessio D. Flucytosine treatment of Candida arthritis. JAMA 1977; 238:1395–6.

105. Specht EE. Candida pyarthrosis of the hip and renal homotransplant. Report of a case treated by femoral head and neck resection and 5-flucytosine. Clin Orthop Relat Res 1977; 126:176–7.

106. Ide A, Iacobelli S, Zenteno G. Candida arthritis associated with positive bile- and drug-resistant crystals without chondrocalcinosis. J Rheumatol 1977; 4:327–8.

107. Businco L, Iannaccone G, Del Principe D, et al. Disseminated arthritis and osteitis by Candida albicans in a two month old infant receiving parenteral nutrition. Acta Paediatr Scand 1977; 66:393–5.

108. Meberg A, Langset A, Sovde A, Kolstad A. Candida septicaemia with chorioreti- nal disease. Clin Orthop Relat Res 1977; 126:176–7.

109. Meberg A, Langset A, Sovde A, Kolstad A. Candida septicaemia with chorioreti- nal disease. Clin Orthop Relat Res 1977; 126:176–7.

110. Meberg A, Langset A, Sovde A, Kolstad A. Candida septicaemia with chorioreti- nal disease. Clin Orthop Relat Res 1977; 126:176–7.

111. Gamaletsou MN, Rammaert B, Bueno MA, et al. Epidemiology, clinical manifes- tations and therapeutic considerations. Semin Arthritis Rheum 1978; 8:142–50.

112. Farrell JB, Person DA, Lidsky MD, et al. Candida tropicalis arthritis - assessment of amphotericin B therapy. J Rheumatol 1978; 5:267–71.

113. Imbeau SA, Hanson J, Langgians G, D’Alessio D. Flucytosine treatment of Candida arthritis. JAMA 1977; 238:1395–6.

114. Specht EE. Candida pyarthrosis of the hip and renal homotransplant. Report of a case treated by femoral head and neck resection and 5-flucytosine. Clin Orthop Relat Res 1977; 126:176–7.

115. Ide A, Iacobelli S, Zenteno G. Candida arthritis associated with positive bile- and drug-resistant crystals without chondrocalcinosis. J Rheumatol 1977; 4:327–8.

116. Businco L, Iannaccone G, Del Principe D, et al. Disseminated arthritis and osteitis by Candida albicans in a two month old infant receiving parenteral nutrition. Acta Paediatr Scand 1977; 66:393–5.